Use of aminoglutethimide for the treatment of advanced breast cancer. Clinical correlations with previous treatment, oestrogen-receptor and menstrual status

W. R. Bezwoda, R. D. Dansey, C. S. Hesdorffer, S. Browde

Research output: Contribution to journalArticlepeer-review

Abstract

In a study of 118 patients with advanced breast cancer treated with aminoglutethimide plus hydrocortisone replacement the overall objective response rate was 42 (36%). Response was not determined either by the nature or the extent of previous treatment, including endocrine therapy and/or chemotherapy, nor by oestrogen-receptor status. The vast majority of patients who responded were postmenopausal but a complete response was seen in a premenopausal patient with skin metastases. Aminoglutethimide is useful in the second-line treatment of postmenopausal subjects with advanced breast cancer.

Original languageEnglish (US)
Pages (from-to)107-109
Number of pages3
JournalSouth African Medical Journal
Volume72
Issue number2
StatePublished - Dec 28 1987

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Use of aminoglutethimide for the treatment of advanced breast cancer. Clinical correlations with previous treatment, oestrogen-receptor and menstrual status'. Together they form a unique fingerprint.

Cite this